title: Liposomal formulation of amphotericin B for the treatment of mucosal leishmaniasis in HIV-negative patients.
abstract: BACKGROUND
  Studies assessing the efficacy of liposomal amphotericin B (LAB) in the treatment of patients with mucosal leishmaniasis (ML) are very scarce in the literature and an optimal dose regimen has not yet been defined.
  
  
  METHODS
  We performed a retrospective and descriptive analysis from records of 16 patients with ML treated with LAB. The mean daily dose of LAB was 2.5 mg/kg/day.
  
  
  RESULTS
  Healing of the lesion was observed in 14 (88%) of the 16 patients. The mean cumulative doses, excluding the two treatment failures, were 2265 mg and 33 mg/kg.
  
  
  CONCLUSIONS
  Liposomal amphotericin B in the cumulative dose of 30 to 35 mg/kg was able to achieve 100% effectiveness.
authors.affiliation: Department of Infectious and Parasitic Diseases, University of São Paulo, Medical School, São Paulo, SP, Brazil.
authors.forename: Carolina
authors.initials: C
authors.lastname: Rocio
authors.forename: Valdir Sabbaga
authors.initials: VS
authors.lastname: Amato
authors.forename: Raphael A
authors.initials: RA
authors.lastname: Camargo
authors.forename: Felipe F
authors.initials: FF
authors.lastname: Tuon
authors.forename: Antonio Carlos
authors.initials: AC
authors.lastname: Nicodemo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000666:Amphotericin B / Q000627:therapeutic use*; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007897:Leishmaniasis, Mucocutaneous / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
chemical_list: D000981:Antiprotozoal Agents; C068538:liposomal amphotericin B; D000666:Amphotericin B
keywords: Amphotericin B; Leishmania treatment; Leishmaniasis